CD274 and neoplasm: The composition of the tumor microenvironment (TME)—especially the quantity and the quality of tumor-infiltrating lymphocytes (TILs), which reflect the tumor immune phenotype—has been shown to influence response to PD-1/PD-L1 inhibitors [30].